References:
1. Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo JJ. High red cell distribution width is an adverse predictive and prognostic factor in patients with diffuse large B-Cell lymphoma treated with chemoimmunotherapy. Clinical Lymphoma Myeloma and Leukemia. 2019;19(9):e551-e7.
2. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine. 2002;346(4):235-42.
3. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Critical reviews in oncology/hematology. 2013;87(2):146-71.
4. Friedberg JW. New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical PracticeDLBCL Gene Expression Profiling. Clinical Cancer Research. 2011;17(19):6112-7.
5. Vaidya R, Witzig T. Prognostic factors for diffuse large B-cell lymphoma in the R (X) CHOP era. Annals of oncology. 2014;25(11):2124-33.
6. Bento L, Díaz‐López A, Barranco G, Martín‐Moreno AM, Baile M, Martín A, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO). British journal of haematology. 2020;188(6):888-97.
7. Chen H, Zhong Q, Zhou Y, Qin Y, Yang J, Liu P, et al. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. BMC cancer. 2022;22(1):583.
8. Li Z-M, Huang J-J, Xia Y, Sun J, Huang Y, Wang Y, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PloS one. 2012;7(7):e41658.
9. Wang J, Zhou X, Liu Y, Li Z, Li X. Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis. PLoS One. 2017;12(4):e0176008.
10. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. American heart journal. 2009;158(4):659-66.
11. Jo YH, Kim K, Lee JH, Kang C, Kim T, Park H-M, et al. Red cell distribution width is a prognostic factor in severe sepsis and septic shock. The American journal of emergency medicine. 2013;31(3):545-8.
12. Lee WS, Kim T-Y. Relation between red blood cell distribution width and inflammatory biomarkers in rheumatoid arthritis. Archives of pathology & laboratory medicine. 2010;134(4):505-6.
13. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Archives of pathology & laboratory medicine. 2009;133(4):628-32.
14. Bick RL, Baker WF. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC). Thrombosis research. 1992;65(6):785-90.
15. Fronas S, Wik HS, Dahm AEA, Jørgensen CT, Gleditsch J, Raouf N, et al. Safety of D‐dimer testing as a stand‐alone test for the exclusion of deep vein thrombosis as compared with other strategies. Journal of Thrombosis and Haemostasis. 2018;16(12):2471-81.
16. Liu B, Li B, Zhou P, Yue W, Wang T, Wang J, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). Clinica Chimica Acta. 2018;482:191-8.
17. Puurunen MK, Enserro D, Xanthakis V, Larson MG, Benjamin EJ, Tofler GH, et al. Biomarkers for the prediction of venous thromboembolism in the community. Thrombosis Research. 2016;145:34-9.
18. Rowbotham B, Whitaker A, Masci P. Plasma cross-linked fibrin degradation product (XLFbDP) assays in an in vivo model of fibrinolysis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 1990;1(6):653-61.
19. Geng Y-d, Chen Y-r, Jin J, Wang X-d, Zhang S, Li D-j. Prognostic value of D-dimer in patients with diffuse large B-cell lymphoma: a retrospective study. Current Medical Science. 2019;39:222-7.
20. Desch A, Gebhardt C, Utikal J, Schneider SW. D‐dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress. International Journal of Cancer. 2017;140(4):914-21.
21. Takeuchi H, Abe M, Takumi Y, Hashimoto T, Miyawaki M, Okamoto T, et al. Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer. Scientific reports. 2019;9(1):1-7.
22. Yao D, Wang Z, Cai H, Li Y, Li B. Relationship between red cell distribution width and prognosis in patients with breast cancer after operation: a retrospective cohort study. Bioscience Reports. 2019;39(7).
23. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PloS one. 2013;8(11):e80240.
24. Wang Y, Zhou Y, Zhou K, Li J, Che G. Prognostic value of pre-treatment red blood cell distribution width in lung cancer: a meta-analysis. Biomarkers. 2020;25(3):241-7.
25. Ai L, Mu S, Hu Y. Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis. Cancer cell international. 2018;18:1-8.
26. Geng Y, Jian C, Yang S, Wu S, Zhou J, Li D. The prognostic value of d-dimer in de novo acute myeloid leukemia. The American Journal of the Medical Sciences. 2016;352(2):129-33.
27. Herraez I, Bento L, Del Campo R, Sas A, Ramos R, Ibarra J, et al. Prognostic role of the red blood cell distribution width (RDW) in Hodgkin lymphoma. Cancers. 2020;12(11):3262.
28. Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. Red cell distribution width as a predictor of prostate cancer progression. Asian Pacific Journal of Cancer Prevention. 2014;15(18):7781-4.
29. Feng J-F, Yang X, Chen S, Zhao Q, Chen Q-X. Prognostic value of plasma D-dimer in patients with resectable esophageal squamous cell carcinoma in China. Journal of Cancer. 2016;7(12):1663.
30. Han F, Liu Y, Cheng S, Sun Z, Sheng C, Sun X, et al. Diagnosis and survival values of neutrophil-lymphocyte ratio (NLR) and red blood cell distribution width (RDW) in esophageal cancer. Clinica Chimica Acta. 2019;488:150-8.
31. Wang P-F, Song S-Y, Guo H, Wang T-J, Liu N, Yan C-X. Prognostic role of pretreatment red blood cell distribution width in patients with cancer: A meta-analysis of 49 studies. Journal of Cancer. 2019;10(18):4305.
32. Yuksel C, Ersen O, Cuclu S, Bakırarar B, Ünal A, Demirci S. Prognostic role of red distribution width (RDW) value in gastric cancer. Journal of the College of Physicians and Surgeons Pakistan. 2021;31(1).
33. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008-12.
34. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10):e1-e34.
35. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011;2(1):1-12.
36. Duan S, Zhang Y, Xu S, Jiang P, Qi Q. Contrast-Enhanced Ultrasound Parameters and D-Dimer: New Prognostic Parameters for Diffuse Large B-Cell Lymphoma. Cancer Management and Research. 2022:2535-44.
37. Hasan KM, Elmeshhedany AY. Prognostic value of absolute lymphocyte/monocyte ratio, red cell distribution width and neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma patients. Cellular and Molecular Biology. 2021;67(3):61-8.
38. Huang H, Fan L, Fu D, Lin Q, Shen J. High pretreatment plasma D-dimer levels predict poor survival in patients with diffuse large B-cell lymphoma in the real world. Translational Cancer Research. 2021;10(4):1723.
39. Li D, Li S, Xia Z, Cao J, Zhang J, Chen B, et al. Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts. EPMA Journal. 2022;13(3):499-517.
40. Li M, Xia H, Zheng H, Li Y, Liu J, Hu L, et al. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients. BMC cancer. 2019;19:1-11.
41. Periša V, Zibar L, Sinčić-Petričević J, Knezović A, Periša I, Barbić J. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. Croatian medical journal. 2015;56(4):334-43.
42. Tanaka A, Shimomura Y, Yabushita T, Ishikawa T. High Pretreatment Plasma D-Dimer Levels Are Associated with Poor Prognosis in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphomas Treated with Immunochemotherapy. Blood. 2018;132:4219.
43. Zhou S, Fang F, Chen H, Zhang W, Chen Y, Shi Y, et al. Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients. Oncotarget. 2017;8(25):40724.
44. Riedl J, Posch F, Königsbrügge O, Lötsch F, Reitter E-M, Eigenbauer E, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. PloS one. 2014;9(10):e111440.
45. Yilmaz A, Malya F, Ozturk G, Çitgez B, Ozdenkaya Y, Ersavas C, et al. Effect of pre-operative red blood cell distribution on cancer stage and morbidity rate in patients with pancreatic cancer. International journal of clinical and experimental medicine. 2014;7(9):3072.
46. Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, et al. Higher red blood cell distribution width is an adverse prognostic factor in chronic-phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Anticancer Research. 2015;35(10):5473-8.
47. Podhorecka M, Halicka D, Szymczyk A, Macheta A, Chocholska S, Hus M, et al. Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. Oncotarget. 2016;7(22):32846.
48. Luo H, Quan X, Song X-Y, Zhang L, Yin Y, He Q, et al. Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma. Oncotarget. 2017;8(54):92522.
49. Wang J, Xie X, Cheng F, Zhou X, Xia J, Qian X, et al. Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. Cancer Biomarkers. 2017;20(3):267-72.
50. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. nature. 2008;454(7203):436-44.
51. Demirkol S, Balta S, Cakar M, Unlu M, Arslan Z, Kucuk U. Red cell distribution width: A novel infl ammatory marker in clinical practice. Cardiology Journal. 2013;20(2):209-.
52. Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. haematologica. 2015;100(1):124.
53. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. haematologica. 2012;97(8):1158-64.
54. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. British journal of cancer. 2002;86(3):389-95.
55. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Japanese journal of clinical oncology. 2001;31(8):388-94.